巴曲酶联合依达拉奉治疗急性脑梗死的临床观察

Observation on Effect of Batroxobin in Combined with Edaravone to Treat Acute Cerebral Infarction Patients

目的:观察与分析巴曲酶联合依达拉奉治疗急性脑梗死的临床效果。方法:回顾性分析本院收治的45例已失去溶栓机会的急性脑梗死患者的临床资料。结果:联合组总有效率和显效率均明显优于巴曲酶组(P<0.05);联合治疗并不影响巴曲酶的降纤作用;治疗前后比较两组的神经功能缺损评分都明显降低(P<0.01),联合组比巴曲酶组获得的改善更显著(P<0.01);两组发生不良反应均少而轻。结论:采用巴曲酶联合依达拉奉的方法可以有效治疗急性脑梗死,并能明显改善患者的神经功能损伤。

Objective： To observe the effect of batroxobin enzymes with edaravone for treatment of acute cerebral infarction. Method： To retrospectively analyze 45 cases who with acute cerebral infarction had lost thrombolysis opportunities. Result： The total efficiency and markedly effective rate of the combined group was significantly better than that of batroxobin group （ P〈0.05 ） . Combination therapy did not affect the batroxobin defibrase role. Compared the two groups of neurological deficit scores before and after treatment, there were significantly lower （ P〈0.01 ） . The combined group improved more significantly than batroxobin group （P〈0.01） . The incidences of adverse reactions of the two groups were few and mild. Conclusion： Batroxobin edaravone method can be effective in treating acute cerebral infarction, and significantly improve the patient＇ s neurological deficit.